Clinical Trial Update: Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating combination of ionizing radiation and ipilimumab in metastatic non-small cell lung cancer has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-11-22